Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alimera Sciences Inc.

This article was originally published in Start Up

Executive Summary

The team that established CIBA Vision Ophthalmics and later worked together at Novartis Ophthalmics has launched specialty ophthalmologic pharma Alimera Sciences Inc. Alimera has moved its first OTC eye care product to market, and plans to begin development of prescription ophthalmic drugs.

You may also be interested in...



Alimera Raises $72 Million In IPO; Clips Share Price To $11 From Initial $15-$17 Range

$15 million will be used to pay debt to Australian drug maker pSivida, which gave Alimera its lead compound.

Alimera Raises $72 Million In IPO; Clips Share Price To $11 From Initial $15-$17 Range

$15 million will be used to pay debt to Australian drug maker pSivida, which gave Alimera its lead compound.

Spotting Switching Opportunities in Ophthalmology

The buzz around ophthalmology is trickling down to company creation. French start-up Fovea will buy in and build compounds tackling the root causes of retinal diseases.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PL000723

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel